Psoriasis patients: does your injection schedule matter?
NCT ID NCT07642544
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at 120 adults with moderate-to-severe psoriasis who take secukinumab, a biologic drug. It compares two maintenance schedules: the standard every-4-week injection versus a non-standard schedule (longer intervals or lower dose). The goal is to see which schedule keeps psoriasis under control longer and how well patients recover if the drug stops working. The study is observational and uses medical records, so it cannot prove cause and effect.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
secukinumab (a biologic drug that targets inflammation)
What this could lead to
If successful, this could help doctors choose the best maintenance schedule for secukinumab to keep psoriasis under control longer.
What could go wrong
This is a small, single-center retrospective study, not a randomized trial. Results may not apply to all patients, and the study only looks back at existing records.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medicine School
Nanjing, Jiangsu, 210008, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact